2010
The Parkinson’ s Progression Markers Initiative( PPMI) launches, creating a landmark longitudinal study of Parkinson’ s and biorepository. As trial sponsor, MJFF immediately begins trial recruitment at six sites to start. Within 13 years, in 2023, samples collected from PPMI participants validate a biomarker of early Parkinson’ s pathology, fundamentally transforming our understanding of the disease.
2014
The Edmond J. Safra Fellowship in Movement Disorders launches with the goal of increasing the number of trained movement disorder specialists. By the end of 2025, the program will have 65 current and graduated Fellows, improving access to care for thousands of people in countries around the world.
2018
The first MJFF-funded Parkinson’ s treatment receives FDA approval— a significant milestone demonstrating the value of the Foundation’ s derisking strategy. Drug development continues to advance, and by 2025, 150 Parkinson’ s treatments are in clinical testing and nearly 50 % of these potential treatments aim to slow or stop PD in its tracks.
2011
Nike generates $ 9.4 million for Parkinson’ s research through an online auction of 1,500 pairs of the iconic self-lacing Nike MAG shoes from Back to the Future Part II.
2012
Fox Trial Finder launches to connect volunteers with clinical trials, centralizing information about research participation and enabling tens of thousands of individuals to sign up for research.
2019
The launch of the Aligning Sciences Across Parkinson’ s( ASAP) initiative, in ongoing partnership with the Sergey Brin Family Foundation, creates a new strategic vision for accelerating the pace of scientific discovery in PD. ASAP quickly deploys funding through three key initiatives: the Collaborative Research Network, the Global Parkinson’ s Genetics Program and an expansion of PPMI.